期刊
EXPERIMENTAL DERMATOLOGY
卷 30, 期 8, 页码 1115-1125出版社
WILEY
DOI: 10.1111/exd.14354
关键词
cancer; cutaneous squamous cell carcinoma; epigenetics; metabolism
类别
资金
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [K08AR070289, R01AR077615]
- Damon Runyon Cancer Foundation
- Dermatology Foundation
With the ageing population and increased recreational sun exposure and immunosuppression, cutaneous squamous cell carcinoma is a significant clinical and economic issue. Despite advances in therapy, new research suggests that epigenetic and metabolic dysregulation may be critical contributors to cSCC pathogenesis and potential therapeutic approaches.
With the ageing of the population and increased levels of recreational sun exposure and immunosuppression, cutaneous squamous cell carcinoma (cSCC), is both an enormous and expanding clinical and economic issue. Despite advances in therapy, up to 5000-8000 people are estimated to die every year from cSCC in the U.S., highlighting the need for both better prevention and treatments. Two emerging areas of scientific discovery that may offer new therapeutic approaches for cSCC are epigenetics and metabolism. Importantly, these disciplines display extensive crosstalk, with metabolic inputs contributing to the chromatin landscape, while the dynamic epigenome shapes transcriptional and cellular responses that feedback into cellular metabolism. Recent evidence suggests that indeed, epigenetic and metabolic dysregulation may be critical contributors to cSCC pathogenesis. Here, we synthesize the latest findings from these fast-moving fields, including how they may drive cSCC, yet also be harnessed for therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据